Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy

Inclusion Criteria: * Metastatic non-small cell lung cancer patient * Adult ≥ 18 years * Starting any 1st, 2nd or 3rd line chemotherapy and/or immunotherapy administered via a central venous catheter (including implanted ports), or receiving the 2nd cycle of aforementioned anticancer treatment * An energy gap of ≥ 40 % and/or 1000 kcal between the target energy intake (30 ± 5 kcal/kg/day) and the actual energy intake at screening, irrespective of weight loss * Functional digestive tract allowing oral intake * If female of childbearing potential, willing to use a sufficiently safe contraception method throughout participation in the study * Signed informed consent from patient or legal representative Exclusion Criteria: * Parenteral nutrition (PN) administered during the preceding month (the sole administration of intravenous glucose is allowed), or standard of care PN planned to start within 3 weeks after baseline visit * More than 1600 kcal/day required as PN * Tube feeding at screening, or planned to start within 3 weeks after baseline visit * Body mass index (BMI) \> 30 kg/m2 * Performance status \> 3 Eastern Cooperative Oncology Group (ECOG) score * Life expectancy \< 3 months * Active bloodstream infection demonstrated by positive blood culture at Screening * Hypersensitivity to fish-, egg, soya- or peanut protein or to any of the active substances or excipients in SmofKabiven E * Severe blood coagulation disorders * Congenital errors of amino acid metabolism * Pathologically elevated serum levels of any of the included electrolytes * General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency * Hemophagocytotic Syndrome * Severe hyperlipidemia (serum triglycerides \> 353 mg/dL) * Severe liver insufficiency: liver enzymes (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], gamma glutamyl transferase \[GGT\]) or conjugated bilirubin exceeding 3 x upper limit of normal range, or International Normalised Ratio (INR) \> 2 * Severe renal dysfunction (estimated glomerular filtration rate \[eGFR\] \< 30 ml/min/1.73m2) and patients on renal replacement therapy * Uncontrolled hyperglycaemia * Unstable conditions (e.g., embolism, metabolic acidosis, hypotonic dehydration) * Pregnancy or lactation * Contraindications to any of the study assessment methods including computer tomography and indirect calorimetry * Participation in a clinical study with an investigational drug or investigational medical device within one month prior to start of study or during study * Prior inclusion in the present study